CY1112039T1 - Οπτικα ισομερη ενος μεταβολιτη ιλοπεριδονης - Google Patents

Οπτικα ισομερη ενος μεταβολιτη ιλοπεριδονης

Info

Publication number
CY1112039T1
CY1112039T1 CY20111101053T CY111101053T CY1112039T1 CY 1112039 T1 CY1112039 T1 CY 1112039T1 CY 20111101053 T CY20111101053 T CY 20111101053T CY 111101053 T CY111101053 T CY 111101053T CY 1112039 T1 CY1112039 T1 CY 1112039T1
Authority
CY
Cyprus
Prior art keywords
holoperidon
isomeri
variable
optical
fouoro
Prior art date
Application number
CY20111101053T
Other languages
Greek (el)
English (en)
Inventor
Dominique Grimler
Hans O Kalkman
Hequn Yin
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1112039T1 publication Critical patent/CY1112039T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicinal Preparation (AREA)
CY20111101053T 2001-08-31 2011-11-02 Οπτικα ισομερη ενος μεταβολιτη ιλοπεριδονης CY1112039T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31639001P 2001-08-31 2001-08-31
EP02767454A EP1425272B1 (en) 2001-08-31 2002-08-30 Optical isomers of an iloperidone metabolite

Publications (1)

Publication Number Publication Date
CY1112039T1 true CY1112039T1 (el) 2015-11-04

Family

ID=23228843

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20111101053T CY1112039T1 (el) 2001-08-31 2011-11-02 Οπτικα ισομερη ενος μεταβολιτη ιλοπεριδονης
CY20131100058T CY1113550T1 (el) 2001-08-31 2013-01-23 Οπτικα ισομερη ενος μεταβολιτη ιλοπεριδονης

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20131100058T CY1113550T1 (el) 2001-08-31 2013-01-23 Οπτικα ισομερη ενος μεταβολιτη ιλοπεριδονης

Country Status (9)

Country Link
US (4) US20050020632A1 (enExample)
EP (2) EP2305656B1 (enExample)
JP (6) JP2005504783A (enExample)
AT (1) ATE518845T1 (enExample)
CY (2) CY1112039T1 (enExample)
DK (2) DK2305656T3 (enExample)
ES (2) ES2398434T3 (enExample)
PT (2) PT2305656E (enExample)
WO (1) WO2003020707A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2358416T3 (es) 2001-10-30 2011-05-10 Novartis Ag Formulaciones de liberación prolongada de iloperidona y polímero en forma de estrella.
SI1497266T1 (sl) 2002-03-27 2008-10-31 Glaxo Group Ltd Derivati kinolina in njihova uporaba kot ligandi 5-ht6
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
EP1558582B1 (en) 2003-07-22 2005-12-21 Arena Pharmaceuticals, Inc. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
GB0322994D0 (en) * 2003-10-01 2003-11-05 Novartis Ag Organic compounds
EP1799865B1 (en) 2004-09-30 2012-06-06 Vanda Pharmaceuticals Inc. Methods for the administration of iloperidone
US20100063093A1 (en) 2007-03-28 2010-03-11 Curt Wolfgang Methods for the administration of iloperidone
US20070262395A1 (en) 2006-05-11 2007-11-15 Gibbons Jasper S Memory cell access devices and methods of making the same
US8008144B2 (en) 2006-05-11 2011-08-30 Micron Technology, Inc. Dual work function recessed access device and methods of forming
US20090306137A1 (en) 2006-05-22 2009-12-10 Wolfgang Curt D Treatment for depressive disorders
WO2008121899A2 (en) 2007-03-29 2008-10-09 Vanda Pharmaceuticals Inc. Method of predicting a predisposition to qt prolongation
US20150259747A1 (en) 2007-03-29 2015-09-17 Vanda Pharmaceuticals Inc. Method of predicting a predisposition to qt prolongation
WO2008128166A1 (en) * 2007-04-13 2008-10-23 Concert Pharmaceuticals Inc. Deuterated derivatives of 4-(6-fluoro-1, 2-benzisoxazol-3-yl) piperidine compounds
EP3075865B1 (en) 2007-05-18 2018-05-09 Vanda Pharmaceuticals Inc. Genetic markers for efficacy of iloperidone in the treatment of psychotic symptoms
US8652776B2 (en) 2007-09-10 2014-02-18 Vanda Pharmaceuticals, Inc. Prediction of QT prolongation based on SNP genotype
EP2254564A1 (en) 2007-12-12 2010-12-01 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
CA2709104C (en) 2007-12-13 2017-06-13 Vanda Pharmaceuticals Inc. Method and composition for treating a serotonin receptor-mediated condition
US8729100B2 (en) 2007-12-13 2014-05-20 Vanda Pharmaceuticals, Inc. Method and composition for treating an alpha adrenoceptor-mediated condition
US20110061014A1 (en) 2008-02-01 2011-03-10 Energyhub Interfacing to resource consumption management devices
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
US7824986B2 (en) 2008-11-05 2010-11-02 Micron Technology, Inc. Methods of forming a plurality of transistor gates, and methods of forming a plurality of transistor gates having at least two different work functions
JP5881597B2 (ja) 2009-04-06 2016-03-09 ヴァンダ ファーマシューティカルズ インコーポレイテッド Ｑｔ延長に対する素因を予測する方法
EP2416779B1 (en) 2009-04-06 2016-03-09 Vanda Pharmaceuticals Inc. Method of predicting a predisposition to qt prolongation based on bai3 gene sequence or product thereof
ES2604102T3 (es) 2009-04-06 2017-03-03 Vanda Pharmaceuticals Inc. Método de tratamiento basado en polimorfismos del gen KCNQ1
WO2010117941A1 (en) 2009-04-06 2010-10-14 Vanda Pharmaceuticals, Inc. Method of predicting a predisposition to qt prolongation based on abcc2 gene sequence or product thereof
BR112012015084A2 (pt) 2009-12-23 2017-03-07 Lupin Ltd composição farmacêutica de liberação lenta de iloperidone
US9000221B2 (en) 2010-09-07 2015-04-07 Symed Labs Limited Processes for the preparation of 4′-[3-[4-(6-Fluoro-1 ,2-benzisoxazol-3-yl)piperidino]propoxy]-3′-methoxyacetophenone and intermediates thereof
WO2012063269A2 (en) 2010-11-12 2012-05-18 Cadila Healthcare Limited Process for preparing iloperidone
CA2865845C (en) 2012-03-14 2020-02-18 Vanda Pharmaceuticals Inc. An iloperidone metabolite for use in the treatment of psychiatric disorders
CA2976383C (en) 2015-02-17 2023-05-23 Vanda Pharmaceuticals Inc. Iloperidone for the treatment of schizophrenia
HK1245660A1 (zh) 2015-06-12 2018-08-31 Axovant Sciences Gmbh 有用於预防和治疗rem睡眠行为障碍的二芳基脲和芳基脲衍生物
WO2017011767A2 (en) 2015-07-15 2017-01-19 Axovant Sciences Ltd. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
CN114941015B (zh) * 2019-02-21 2024-05-03 深圳艾欣达伟医药科技有限公司 制造高镜像选择性二级醇的方法
US11607408B2 (en) 2019-10-15 2023-03-21 Vanda Pharmaceuticals Inc. Method of treatment of schizophrenia
WO2023201182A1 (en) 2022-04-13 2023-10-19 Vanda Pharmaceuticals Inc. Treatment of parkinson's disease and parkinson's disease psychosis
WO2024137439A1 (en) 2022-12-19 2024-06-27 Vanda Pharmaceuticals Inc. Dosage regime of iloperidone for treating bipolar i disorder and schizophrenia
KR20260019503A (ko) 2023-06-02 2026-02-10 반다 파마슈티칼즈, 인코퍼레이티드. 일로페리돈을 사용한 치료 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
US5158952A (en) * 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
US5364866A (en) * 1989-05-19 1994-11-15 Hoechst-Roussel Pharmaceuticals, Inc. Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics
US5776963A (en) 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
ES2076253T3 (es) * 1989-05-19 1995-11-01 Hoechst Roussel Pharma N-(ariloxialquil)-heteroarilpiperidinas y -heteroarilpiperazinas, un procedimiento para su preparacion y su uso como medicamentos.
JPH05286868A (ja) 1992-04-03 1993-11-02 Kiyoshi Okawa 制がん剤複合体およびそのスクリーニング法
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
US6172099B1 (en) * 1997-07-03 2001-01-09 Asahi Kasei Kogyo Kabushiki Kaisha Tricyclic compounds having saturated rings and medicinal compositions containing the same
EP1551393A4 (en) 2002-07-30 2010-06-16 Peter Migaly COMBINATION OF THERAPY FOR DEPRESSION, PREVENTION OF SUICIDE AND VARIOUS MEDICAL AND PSYCHIATRIC DISORDERS

Also Published As

Publication number Publication date
US8314129B2 (en) 2012-11-20
DK2305656T3 (da) 2013-02-11
HK1156309A1 (en) 2012-09-07
WO2003020707A1 (en) 2003-03-13
ES2398434T8 (es) 2017-10-09
JP2013116905A (ja) 2013-06-13
HK1066536A1 (en) 2005-03-24
PT2305656E (pt) 2013-01-10
US20110201646A1 (en) 2011-08-18
EP2305656B1 (en) 2012-10-24
JP2005504783A (ja) 2005-02-17
DK1425272T3 (da) 2011-11-21
ES2370634T3 (es) 2011-12-21
JP2015227368A (ja) 2015-12-17
ES2398434T3 (es) 2013-03-19
EP2305656A1 (en) 2011-04-06
US20130296366A1 (en) 2013-11-07
ATE518845T1 (de) 2011-08-15
CY1113550T1 (el) 2016-06-22
US7977356B2 (en) 2011-07-12
JP2015214577A (ja) 2015-12-03
US20050020632A1 (en) 2005-01-27
US20090176739A1 (en) 2009-07-09
JP2013227335A (ja) 2013-11-07
JP2010100633A (ja) 2010-05-06
EP1425272A1 (en) 2004-06-09
EP1425272B1 (en) 2011-08-03
PT1425272E (pt) 2011-10-19

Similar Documents

Publication Publication Date Title
CY1113550T1 (el) Οπτικα ισομερη ενος μεταβολιτη ιλοπεριδονης
NO20051965L (no) Nye piperidinderivater for anvendelse ved behandling av kemokinmedierte sykdomstilstander.
HRP20090281T1 (hr) 1,2,3,4-tetrasubstituirani indol za liječenje respiratornih bolesti
HRP20080226T3 (en) Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors
NO20051527D0 (no) 3-(sulfonamidoetyl) -indol-derivater for anvendelse som glukocorticoid-mimetica ved behandling av inflammatoriske, allergiske og proliferative sykdommer.
NO20062370L (no) Amidderivater
DE60233043D1 (de) 2-iminoimidazolderivate
UA94390C2 (ru) Применение производных индолинонов, предназначенных для лечения или предупреждения идиопатического фиброза легких
HRP20080446T3 (en) Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine
DE602004016850D1 (de) Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren
DE50313324D1 (de) Disubstituierte pyrazolylcarboxanilide
ATE498600T1 (de) Inden derivate als pharmazeutika
NO20065327L (no) Fremgangsmate for fremstilling av derivarer av 5-'4-(2-hydroksy-propyl)-3,5-dihydro-3H'1, 2,4(triazin-2-yl)-benzamid.
ATE360612T1 (de) In 4-stellung substituierte piperidinderivate
DE602004009079D1 (de) Carbostyril-derivative zur beschleunigten speichelabsonderung
NO20054225L (no) Benzamid-derivater som oksytocin-agonister og vasopressin-antagonister
NO20072587L (no) Fenyldiazepankarboksamider og anilerte fenylpiperazinkarboksamider inneholdende oksygen og benyttet som dopamin D3 antagonister
EA200401290A1 (ru) НЕКОТОРЫЕ ПРОИЗВОДНЫЕ 1-(D-ЦИКЛОПРОПИЛГЛИЦИНИЛ)-4-(ПИПЕРИДИН-4-ИЛ)ПИПЕРАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ СЕРИНПРОТЕАЗЫ ФАКТОРА Xa
ATE322479T1 (de) Benzamidinderivate
DK1384476T3 (da) Azolylcarbinolderivater af aryl (eller heteroaryl) til behandling af åndedrætssygdomme
HRP20030653B1 (en) Novel benzoylguanidine salt
AR026673A1 (es) Benzoilpirazoles sustituidos por 3-(4,5-dihidroisoxazol-3-ilo)
ATE389326T1 (de) 3-cyclopropyl-4-(3-amino-2-methylbenzoyl)pyrazo e und ihre verwendung als herbizide
DE602005005638D1 (de) 2-(piperidin-4-yl)-4,5-dihydro-2h-pyridazin-3-on-derivate als pde4-inhibitoren
NO20056188L (no) Anvendelse av en c-Abl-, PDGF-R- eller c-kit-tyrosinkinaseinhibitor for behandling av diabetes